TABLE 4.
COVID‐19 vaccines approved by at least one country. 106
| Vaccine name | Vaccine platform | Manufacturer | Number of countries approving | Number of trials |
|---|---|---|---|---|
| Zifivax (ZF2001) | Protein subunit | Anhui Zhifei Longcom, Beijing, People's Republic of China | 4 countries | 21 trials in 5 countries |
| Noora vaccine | Protein subunit | Bagheiat‐Allah University of Medical Sciences, Tehran, Iran | 1 country | 3 trials in 1 country |
| Covaxin (BBV152) | Inactivated | Bharat Biotech, Hyderabad, India | 14 countries | 16 trials in 2 countries |
| iNVOVACC | Nonreplicating viral vector | Bharat Biotech, Hyderabad, India | 1 country | 4 trials in 1 country |
| Corbevax (BECOV2A) | Protein subunit | Biological E Limited, Hyderabad, India | 2 countries | 7 trials in 1 country |
| Convidecia Air (Ad5‐nCoV‐IH) | Nonreplicating viral vector | CanSino, Tianjin, People's Republic of China | 2 countries | 5 trials in 4 countries |
| Convidecia (Ad5‐nCoV) | Nonreplicating viral vector | CanSino, Tianjin, People's Republic of China | 10 countries | 14 trials in 6 countries |
| Abdala (CIGB‐66) | Protein subunit | Cuban Center for Genetic Engineering and Biotechnology, Havana, Republic of Cuba | 6 countries | 5 trials in 1 country |
| KoviVac | Inactivated | Chumakov Federal Scientific Center for Research and Development of Immune‐and‐Biological Products of Russian Academy of Sciences, Moscow, Russian Federation | 3 countries | 3 trials in 1 country |
| Gam‐COVID‐Vac (Sputnik, rAd5) | Nonreplicating viral vector | Gamaleya National Center of Epidemiology and Microbiology, Moscow, Russian Federation | 1 country | 2 trials in 0 countries |
| Sputnik Light | Nonreplicating viral vector | Gamaleya National Center of Epidemiology and Microbiology, Moscow, Russian Federation | 26 countries | 7 trials in 3 countries |
| Sputnik V (Gam‐COVID‐Vac) | Nonreplicating viral vector | Gamaleya National Center of Epidemiology and Microbiology, Moscow, Russian Federation | 74 countries | 25 trials in 8 countries |
| GEMCOVAC‐19 | RNA | Gennova Biopharmaceuticals Limited, Maharashtra, India | 1 country | 2 trials in 1 country |
| Turkovac (ERUCOV‐VAC) | Inactivated | Health Institutes of Turkey, Istanbul, Turkey | 1 country | 8 trials in 1 country |
| Soberana 02 (FINLAY‐FR‐2, Pastu Covac) | Protein subunit | Instituto Finlay de Vacunas Cuba, Havana, Republic of Cuba | 4 countries | 7 trials in 2 countries |
| Soberana Plus (FINLAY‐FR‐1A) | Protein subunit | Instituto Finlay de Vacunas Cuba, Havana, Republic of Cuba | 2 countries | 5 trials in 1 country |
| Jcovden (Ad26.COV2.S) | Nonreplicating viral vector | Janssen (Johnson & Johnson), Beerse, Belgium | 113 countries | 26 trials in 25 countries |
| V‐01 | Protein subunit | Livzon Mabpharm Inc., Guanghong, China | 1 country | 7 trials in 3 countries |
| Covifenz (CoVLP, MT‐2766, Plant‐based virus‐like particle [VLP]) | VLP | Medicago, Quebec City, Canada | 1 country | 6 trials in 6 countries |
| MVC‐COV1901 | Protein subunit | Medigen, Taipei, Taiwan, People's Republic of China | 4 countries | 15 trials in 4 countries |
| Spikevax (mRNA‐1273, Elasomeran) | RNA | Moderna, Cambridge, MA, USA | 88 countries | 70 trials in 24 countries |
| Spikevax Bivalent Original/Omicron BA.1 | RNA | Moderna, Cambridge, MA, USA | 38 countries | 5 trials in 4 countries |
| Spikevax Bivalent Original/Omicron BA.4/BA.5 | RNA | Moderna, Cambridge, MA, USA | 33 countries | 2 trials in 1 country |
| Recombinant SARS‐CoV‐2 Vaccine (CHO Cell, NVSI‐06‐08) | Protein subunit | National Vaccine and Serum Institute, Beijing, People's Republic of China | 1 country | 3 trials in 2 countries |
| Nuvaxovid (NVX‐CoV2373) | Protein subunit | Novavax, Gaithersburg, MD, USA | 40 countries | 22 trials in 14 countries |
| FAKHRAVAC (MIVAC) | Inactivated | Organization of Defensive Innovation and Research, Tehran, Iran | 1 country | 3 trials in 1 country |
| Vaxzevria (AZD1222, ChAdOx1 nCoV‐19) | Nonreplicating viral vector | Oxford University/AstraZeneca, Södertälje, Sweden | 149 countries | 73 trials in 34 countries |
| Comirnaty (BNT162b2, Tozinameran) | RNA | Pfizer/Biontech, Mainz, Germany | 149 countries | 100 trials in 31 countries |
| Comirnaty Bivalent Original/Omicron BA.1 | RNA | Pfizer/Biontech, Mainz, Germany | 35 countries | 3 trials in 5 countries |
| Comirnaty Bivalent Original/Omicron BA.4/BA.5 | RNA | Pfizer/Biontech, Mainz, Germany | 33 countries | 4 trials in 1 country |
| IndoVac | Protein subunit | PT Bio Farma, Jawa Barat Indonesia | 1 country | 4 trials in 1 country |
| Razi Cov Pars | Protein subunit | Razi Vaccine and Serum Research Institute, Karaj, Iran | 1 country | 5 trials in 1 country |
| QazVac (QazCovid‐in) | Inactivated | Research Institute for Biological Safety Problems, Guardeyskiy, Republic of Kazakhstan | 2 countries | 3 trials in 1 country |
| VidPrevtyn Beta | Protein subunit | Sanofi/GSK | 30 countries | 3 trials in 2 countries |
| Covishield (Oxford/ AstraZeneca formulation) | Nonreplicating viral vector | Serum Institute of India, Pune, India (based on AstraZeneca technology) | 49 countries | 6 trials in 1 country |
| COVOVAX (Novavax formulation) | Protein subunit | Serum Institute of India, Pune, India (based on Novavax technology) | 6 countries | 7 trials in 3 countries |
| KCONVAC (SARS‐CoV‐2 Vaccine (Vero Cells), KconecaVac | Inactivated | Shenzhen Kangtai Biological Products Co., Shenzhen, China | 2 countries | 7 trials in 1 country |
| COVIran Barekat (COVID‐19 Inactivated Vaccine) | Inactivated | Shifa Pharmed Industrial Co, Karaj, Iran | 1 country | 6 trials in 1 country |
| Covilo (BBIBP‐CorV (Vero Cells)) | Inactivated | Sinopharm (Beijing), People's Republic of China | 93 countries | 39 trials in 18 countries |
| Inactivated (Vero Cells) | Inactivated | Sinopharm (Wuhan), People's Republic of China | 2 countries | 9 trials in 7 countries |
| CoronaVac | Inactivated | Sinovac, Beijing, People's Republic of China | 56 countries | 42 trials in 10 countries |
| SKYCovione | Protein subunit | SK Bioscience Co. Ltd., Republic of Korea | 1 country | 7 trials in 6 countries |
| TAK‐019 (NovaVax formulation) | Protein subunit | Takeda, Tokyo, Japan (based on Moderna technology) | 1 country | 3 trials in 1 country |
| TAK‐919 (Moderna formulation) | RNA | Takeda, Tokyo, Japan (based on Moderna technology) | 1 country | 2 trials in 1 country |
| VLA2001 | Inactivated | Valneva, Saint‐Herblain, France | 33 countries | 9 trials in 4 countries |
| SpikoGen (COVAX‐19) | Protein subunit | Vaxine/CinnaGen Co., Tehran, Iran | 1 country | 8 trials in 2 countries |
| Aurora‐CoV (EpiVacCorona‐N) | Protein subunit | “Vector,” National Research Center for Virology and Biotechnology, Novosibirsk, Russian Federation | 1 country | 2 trials in 1 country |
| EpiVacCorona | Protein subunit | “Vector,” National Research Center for Virology and Biotechnology, Novosibirsk, Russian Federation | 4 countries | 4 trials in 1 country |
| AWcorna | RNA | Walvax, Yunnan, China | 1 country | 4 trials in 3 countries |
| ZyCoV‐D | DNA | Zydus Cadila, Ahmedabad, India | 1 country | 6 trials in 1 country |